Introduction To compare the functional and anatomic outcomes between eyes in patients with diabetic macular edema (DME) who underwent a complete anti-vascular endothelial growth factor (VEGF) loading dose with aflibercept and those who were switched to dexamethasone intravitreal (DEX) implant after an incomplete anti-VEGF treatment regimen during the coronavirus disease 2019 (COVID-19) pandemic. Methods This was a retrospective and comparative study conducted on patients with DME. Main outcome measures were mean change in best corrected visual acuity (BCVA) and central retinal thickness (CRT) from baseline to month 4. Results Forty-three eyes (23 eyes in the anti-VEGF group and 20 eyes in the DEX group) were included. Mean BCVA significantly improved from 37.7 +/- 25.3 and 35.7 +/- 22.0 letters at baseline to 45.4 (23.9) (mean adjusted BCVA improvement 7.6 +/- 20.8 letters, p = 0.033) and 46.1 +/- 26.0 (mean adjusted BCVA improvement 10.6 +/- 15.9 letters, p = 0.049) at month 4 in the anti-VEGF and DEX groups, respectively, with no significant differences between study groups (mean adjusted BCVA difference 2.8 letters, 95% CI - 9.4 to 14.9 letters, p = 0.648). There were no statistically significant differences in the proportion of eyes that achieved a BCVA improvement of >= 5, >= 10, and >= 15 letters between groups. CRT was significantly reduced from baseline to month 4 in both DEX (mean adjusted CRT reduction 167.3 +/- 148.2 mu m, p = 0.012) and anti-VEGF groups (mean adjusted CRT reduction 109.9 +/- 181.9 mu m, p < 0.001), with no differences between them (mean adjusted CRT difference 56.1 mu m, 95% CI - 46.0 to 158.2 mu m, p = 0.273). Of 20 eyes in the DEX group, 16 (80.0%) and 9 (45.0%) eyes achieved a CRT reduction of >= 20% from baseline at 2 months and at 4 months, respectively. Conclusions Our results seem to suggest that DEX implant can significantly improve both functional and anatomic clinical outcomes in patients who were unable to complete anti-VEGF loading dose during the COVID-19 pandemic.

Intravitreal Dexamethasone Implant in Patients Who Did Not Complete Anti-VEGF Loading Dose During the COVID-19 Pandemic: a Retrospective Observational Study

Yu, Angeli Christy;Simonelli, Francesca;
2021

Abstract

Introduction To compare the functional and anatomic outcomes between eyes in patients with diabetic macular edema (DME) who underwent a complete anti-vascular endothelial growth factor (VEGF) loading dose with aflibercept and those who were switched to dexamethasone intravitreal (DEX) implant after an incomplete anti-VEGF treatment regimen during the coronavirus disease 2019 (COVID-19) pandemic. Methods This was a retrospective and comparative study conducted on patients with DME. Main outcome measures were mean change in best corrected visual acuity (BCVA) and central retinal thickness (CRT) from baseline to month 4. Results Forty-three eyes (23 eyes in the anti-VEGF group and 20 eyes in the DEX group) were included. Mean BCVA significantly improved from 37.7 +/- 25.3 and 35.7 +/- 22.0 letters at baseline to 45.4 (23.9) (mean adjusted BCVA improvement 7.6 +/- 20.8 letters, p = 0.033) and 46.1 +/- 26.0 (mean adjusted BCVA improvement 10.6 +/- 15.9 letters, p = 0.049) at month 4 in the anti-VEGF and DEX groups, respectively, with no significant differences between study groups (mean adjusted BCVA difference 2.8 letters, 95% CI - 9.4 to 14.9 letters, p = 0.648). There were no statistically significant differences in the proportion of eyes that achieved a BCVA improvement of >= 5, >= 10, and >= 15 letters between groups. CRT was significantly reduced from baseline to month 4 in both DEX (mean adjusted CRT reduction 167.3 +/- 148.2 mu m, p = 0.012) and anti-VEGF groups (mean adjusted CRT reduction 109.9 +/- 181.9 mu m, p < 0.001), with no differences between them (mean adjusted CRT difference 56.1 mu m, 95% CI - 46.0 to 158.2 mu m, p = 0.273). Of 20 eyes in the DEX group, 16 (80.0%) and 9 (45.0%) eyes achieved a CRT reduction of >= 20% from baseline at 2 months and at 4 months, respectively. Conclusions Our results seem to suggest that DEX implant can significantly improve both functional and anatomic clinical outcomes in patients who were unable to complete anti-VEGF loading dose during the COVID-19 pandemic.
2021
Scorcia, Vincenzo; Giannaccare, Giuseppe; Gatti, Valentina; Vaccaro, Sabrina; Piccoli, Gabriele; Villì, Annarita; Toro, Mario Damiano; Yu, ANGELI CHRI...espandi
File in questo prodotto:
File Dimensione Formato  
40123_2021_Article_395.pdf

accesso aperto

Descrizione: versione editoriale
Tipologia: Full text (versione editoriale)
Licenza: Creative commons
Dimensione 377.19 kB
Formato Adobe PDF
377.19 kB Adobe PDF Visualizza/Apri

I documenti in SFERA sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11392/2494420
Citazioni
  • ???jsp.display-item.citation.pmc??? 7
  • Scopus 15
  • ???jsp.display-item.citation.isi??? 15
social impact